All subjects gave informed consent to their participation, and the study was approved by the regional Ethical
Committee. All subjects stated they were free of disease at the time of the study, and none had any known chronic or recurrent illness or was taking any medica- respective markers were transformed to the correspond- and TPA significantly exceeded the within-series variance in 14,13, and 7 subjects (ANOVA, F-test), indicating that the mean concentrations significantly changed with time (Table 2 ). CA 15.3 means changed in 14 subjects, CEA in 13, and TPA in 7. A significant change was observed in nine subjects for one marker, in eight for two markers, and in three for all three markers. In one subject (no. 2), none of the marker concentrations changed significantly between the series. In subject no. 22, only one series of blood samples was drawn; her results are therefore not included in Figure 3 and Table 2 . 
DiscussIon
Here we estimated for monitoring breast cancer patients the variation in sequential serum CA 15.3, CEA, and TPA concentrations accounted for by analytical imprecision and normal intraindividual biological variation. On the basis of the precision profiles of the assays and an average intraindividual biological variation obtained from a group of healthy women, we elaborated a model for estimating the significance of a change in sequential CA 15.3, CEA, and TPA concentrations at different levels of probability.
Conventional cutoff limits
were of little value in detecting unusual results for a particular subject, as CA 15.3, CEA, and TPA concentrations showed marked individuality.
Apparently, the less specific the marker, the greater the biological variation. The best homeostatic regulation within an individual ((Ne) and also the smallest interindividual differences (CVG) were found for CA 15.3 (CV 6.2%, (NG 62.9%) and CEA (CV 9.3%, CV0 86.8%). The greatest biological variation, both intraand interindividually, was found for TPA ((Ne 28.3%, CVQ 133%). The (N for TPA was mainly due to shortterm variation, and that for CA 15.3 and CEA mainly to long-term variation, as indicated by the fewer P values <0.05 for TPA than for CA 15.3 and CEA for changes in between-series within-subject means ( Table 2 Table 2 ). The high probability for the significance of changes in Table 2 N  (21, 22) . The (NA will vary throughout the working range of any assay, and appropriate data must be used to calculate significant changes (Figure 1) . Although an individual's biological variation should be preferred over a population-based average one, the observations necessary to determine an individual's biological variation may not be available.
Owing to different magnitudes of (N (Figure 2) , application of a populationbased average variation implies that the significance of a change will be underestimated for some and overestimated for others. The selected probability level (Z value) for estimating the significance of a change should depend on whether high sensitivity or high specificity is considered important for the monitoring situation in question (17, 19) .
The relation between (NG (Figure 2) . The TPA concentrations, however, were frequently above the cutoff ( Figure   2C ), so that the low index of individuality appeared to have no impact on the distribution of the TPA concentrations in relation to the normal range. This is, however, an invalid conclusion: Clearly, the cutoff limit for TPA has been set much too low. The considerable individuality reported both here and by others (23) means that the interval of results that is usual for an individual spans only a small part of the normal range ( Figure  2 ). Significant changes in results may occur within the normal range, and changes from within to outside the normal range or vice versa are not necessarily significant (Table 2, Figure 3) . Therefore, the use of cutoff limits is inappropriate both for the initial identification of malignancy and during the follow-up of treated patients.
Studies on serial monitoring of serum tumor markers in breast cancer patients often applied one of the following approaches for marker evaluation: (a) a 10-25% change in tumor marker concentrations was considered indicative of changed disease activity (24-27); (b) a difference in concentrations exceeding the analytical imprecision for the assay was considered as response or progression (28); or (c) an increment above the cutoff limit had to be confirmed by a further measurement before being considered as recurrence (29-31). However, a common feature of the reports was that falsepositive marker signals occurred frequently.
Even time-series models have been proposed for evaluating CEA information during postoperative monitoring of breast cancer patients (32 
